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Targeting the genome stability hub Ctf4 by stapled-peptide design 
Yuteng Wu[a], Fabrizio Villa[b], Joseph Maman[c], Yu H Lau[a], Lina Dobnikar[a], Aline C Simon[c], Karim 
Labib[b], David R Spring[a]*, Luca Pellegrini[c]* 
 
Abstract: Exploitation of synthetic lethality by small-molecule 
targeting of pathways that maintain genomic stability is an attractive 
chemotherapeutic approach. The Ctf4/AND-1 protein hub that links 
DNA replication, repair and chromosome segregation represents a 
novel target for the synthetic lethality approach. Here we report the 
design, optimization, and validation of double-click stapled peptides 
encoding the Ctf4-interacting peptide (CIP) of the replicative helicase 
subunit Sld5. Screening stapling positions in the Sld5 CIP, we 
identified an unorthodox i,i+6 stapled peptide with improved, sub-
micromolar binding to Ctf4. The mode of interaction with Ctf4 was 
confirmed by a crystal structure of the stapled Sld5 peptide bound to 
Ctf4. The stapled Sld5 peptide was able to displace the Ctf4-partner 
DNA polymerase  from the replisome in yeast extracts. Our study 
provides proof-of-principle evidence for the development of small-
molecule inhibitors of the human-CTF4 orthologue AND-1.  
Targeting cancer cells with DNA-damaging agents such as cis-platin 
is a mainstay of traditional chemotherapy, and its effectiveness might 
reflect the underlying fragility of cancer cells in maintaining their 
genomic stability[1]. More recently, the concept of synthetic lethality as 
the Achilles heel of cancer cells with defective pathways of genome 
stability maintenance has taken firm hold, since the pioneering 
observations that breast cancer susceptibility protein 2 (BRCA2)-null 
cancer cells are exquisitely sensitive to inhibitors of poly(ADP-ribose) 
polymerase (PARP)[2,3]. Alongside DNA-damaging agents, small-
molecule inhibitors of proteins with essential roles in DNA synthesis, 
such as the DNA polymerase inhibitor fludarabine[4,5] and 
topoisomerase inhibitors camptothecin and etoposide[6,7], are 
currently used in clinical practice. As DNA replication and repair 
processes cooperate to preserve genomic integrity, synthetic lethality 
effects might exist, and should be searched for, among all 
chromosome instability (CIN) genes.  
A distinctive feature of metabolic processes such as DNA 
replication, repair and transcription is the high degree of conservation 
of their protein components among eukaryotes. This observation has 
recently been exploited to screen CIN genes in yeast, as a quick way 
of identifying potentially druggable candidates displaying synthetic 
lethality with DNA repair genes that are often mutated in human 
cancers[8-9]. Such analysis highlighted Ctf4 (Chromosome 
Transmission Fidelity 4)[10,11] as a highly promising candidate, at a 
centre of a web of negative genetic interactions with other CIN genes. 
Moreover, the same appears to be true for the human orthologue of 
yeast Ctf4, AND-1[12]. The high level of genetic connections involving 
Ctf4 is likely to reflect its known role as a protein hub linking different 
processes pertaining to chromosome stability, such as DNA 
replication and sister chromatid cohesion [13,14] (Scheme 1).  
Ctf4 does not possess intrinsic enzymatic activity and therefore 
lacks an active site, making it harder to target with traditional small-
molecule screening strategies. Our recent work has elucidated a key 
mechanism of recruitment to Ctf4 of its protein partners: binding is 
mediated by a short linear motif (SLIM)[15,16], known as the Ctf4-
interacting peptide (CIP), which docks in -helical form onto an 
exposed site on the helical domain of Ctf4, fused to Ctf4’s second -
propeller domain (Figure 1)[13,14]. The interaction is of moderate, 
micromolar affinity and represents an example of the SLIM-protein 
interactions that characterise the dynamic architecture of the 
replisome[17]. The ability of Ctf4 to act as a protein hub depends on its 
trimerisation state, which allows it to interact simultaneously with 
multiple partners[13,14]. Previous evidence had shown that the three 
binding sites in the Ctf4 trimer are independent[13,14]. At present there 
is no clear indication whether binding of client proteins to Ctf4 is 
regulated. The determination of the structural basis for the interaction 
of Ctf4 with its client proteins has afforded an opportunity to develop 
a strategy for targeting Ctf4, by interfering with its function as a protein 
hub. 
Scheme 1. The drawing summarises our current understanding of Ctf4 function 
in the eukaryotic replisome, as a protein hub connecting replisome components 
such as the DNA helicase CMG (Cdc45-MCM-GINS) and DNA polymerase , 
as well as other factors such as the Dna2 helicase-nuclease and the Chl1 
helicase. The oval inset shows a ribbon representation of the Ctf4CTD trimer in 
purple, with bound CIPs as yellow cylinders. Note that the CMG helicase 
comprises Cdc45, the GINS hetero-tetramer (made up of the Psf1, Psf2, Psf3 
and Sld5 subunits) and the MCM2-7 hetero-hexamer, as . The CIP of the CMG 
helicase is located within the Sld5 subunit of GINS.  
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Targeting protein-protein interfaces (PPIs) as a means of 
specifically disrupting the association between macromolecules 
would increase greatly the range of druggable protein targets, and 
a lot of effort has gone into developing effective PPI inhibitors[18-
20]. The application of small-molecule approaches to inhibit PPIs 
can be challenging, as such interfaces consist usually of large and 
relatively flat surfaces, although some notable successes have 
been reported[21-22]. A promising approach to generate -helical 
PPI inhibitors is the use of conformationally-constrained peptides, 
often referred to as ‘stapled peptides’, especially when referring 
to a peptide constrained into an -helical conformation[23-25]. In 
addition to their potential value as inhibitors, stapled peptides 
represent useful proof-of-principle tools to identify targetable 
interactions of interesting proteins with their physiological 
partners, and to dissect biological pathways.  
Peptide stapling is a macrocyclisation approach in which 
helical peptides are covalently modified by the formation of a 
chemical linkage (staple) between side chains of two amino 
acids[26]. The residues to be linked together are usually located on 
the same face of the peptide helix, and separated by one, two or 
three helical turns, so that one amino acid at position i is linked to 
position i+4, i+7 or i+11, respectively. Stapling can constrain -
helical peptides into their bioactive conformation, improving target 
affinity and overall pharmacokinetics[27]. Complementary stapling 
approaches using double cysteine-modified peptides have also 
been developed[28]. 
When optimised, peptide stapling can generate potent 
inhibitors of intracellular PPI targets[29-33]. We have recently 
pioneered a two component double-click stapling technique that 
makes use of double Cu(I)-catalysed azide-alkyne cycloaddition 
(CuAAC) between diazido peptides with dialkynyl staple 
linkages[34,35]. This approach enables a range of different stapled 
peptides to be efficiently generated by reacting a single linear 
diazido peptide with a collection of different dialkynyl stapling 
linkages (Scheme 2). 
Scheme 2. Double-click peptide stapling. The diazido-peptide is combined with 
different dialkynyl staples under CuI catalysis to obtain several bis-triazole 
stapled peptides. 
In this paper, we describe the design of a stapled peptide 
targeting the interaction of Ctf4 with its client proteins, based on 
the CIP sequence present in the GINS Sld5 subunit of the 
replicative helicase complex Cdc45-MCM-GINS (CMG)[13]. The 
most-effective stapled peptide bound to Ctf4 in the same fashion 
as the wild-type sequence, as determined by X-ray 
crystallography of the Sld5 CIP bound to Ctf4 C-terminal domain 
(Ctf4CTD), but with about 10-fold increased affinity. Interestingly, 
the -helix of the stapled peptide was conformationally 
constrained by an unorthodox i,i+6 spacing; to the best of our 
knowledge, this is the first time that the i,i+6 constraint has been 
used to improve helical content and target binding. Furthermore, 
the stapled CIP was able to disrupt the biochemical interaction 
between Ctf4CTD and GINS in vitro and to detach the Ctf4-client 
protein DNA polymerase  from the replisome in yeast extracts. 
Our study provides the first proof-of-principle evidence that it is 
possible to develop chemical tools to target the Ctf4 hub in the 
eukaryotic replisome. 
Figure 1. A Two views of the Ctf4CTD - Sld5 CIP interface (PDB ID 4c95). B 
Front view of the Ctf4CTD - Sld5 interface. Ctf4 is shown as a molecular surface, 
coloured according to electrostatic potential, from blue (10 kcal/mol·e) to red (-
10 kcal/mol·e). The Sld5 CIP is shown as ribbon, with the side chains of acidic 
residues drawn as sticks. CIP C Sequence of the wild-type Sld5 CIP and of the 
A, B, C and D peptides. The stapling positions in each peptide are marked as X 
(all X = Orn(N3)). The stapling positions of the A, B, C and D peptides are also 
shown mapped onto the structure of the Sld5 CIP bound to Ctf4CTD, in four 
separate panels. 
We had previously found that the GINS subunit Sld5 helps to 
anchor Ctf4 to the CMG helicase, and showed that binding is 
mediated by the interaction of a short sequence motif of Sld5 
(Sld5 CIP; 1-MDINIDDILAELDKETTAV-19) with an exposed site 
in the helical domain of the Ctf4CTD structure[13] (Figure 1A). 
Alanine-scanning mutagenesis had revealed that the hydrophobic 
amino acids I5, I8 and L9 at the binding interface were critical for 
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interaction with Ctf4, and that L12 contributed to the interaction 
(Figure 1A)[13]. In addition to the hydrophobic interactions, the Ctf4 
- Sld5 interface displays an electrostatic character due to charge 
complementarity between the acidic CIP motif and the basic 
residues lining the CIP-binding site in Ctf4 (Figure 1B).  
Keeping the key residues in place, four different stapling 
positions were designed into the Sld5 sequence by inspection of 
the Ctf4CTD - Sld5 complex structure (PDB id: 4c95), including two 
sequences with conventional stapling at i,i+7 and two unorthodox 
i,i+6 and i,i+8 staplings (Figure 1C). The diazido-peptides CF-A, 
CF-B, CF-C, CF-D (Figure 1C), where ‘CF’ represents N-terminal 
capping with 5(6)-carboxyfluorescein, were synthesised on Rink 
amide resin using automated solid-phase peptide synthesis. 
Copper-catalysed double-click macrocyclisations were 
subsequently performed with 1,3-diethynylbenzene (staple 1 in 
Scheme 2) to generate the corresponding bis-triazole stapled 
peptides CF-A1, CF-B1, CF-C1 and CF-D1. 
 
Figure 2. A Fluorescence polarisation (FP) measurements of the affinity of 
stapled Sld5 CIPs towards Ctf4CTD. Concentration values in A and B refer to the 
Ctf4CTD protomer. A FP curves for stapled peptides A1 to D1, differing in stapling 
position. The binding curve for the unstapled Sld5 CIP (Sld5 amino acids 1 to 
19) is also reported. B FP curves for Sld5 CIPs stapled at i, i+6 (position A) with 
staple scaffolds 2 to 4. C FP competition experiment between wild-type Sld5 
CIP and the stapled A2 peptide. 
The Sld5-based stapled peptides were first evaluated for 
their ability to bind Ctf4CTD in a fluorescence anisotropy (FP) assay, 
using peptides that had been N-terminally labelled with carboxy-
fluorescein. The i,i+6 stapled peptide A1 displayed a stronger 
binding affinity for Ctf4CTD (Kd = 0.84 ± 0.19 μM) compared to the 
wild-type peptide Sld51-19 (Kd = 3.5 ± 0.2 μM), whereas the i,i+7 
stapled peptides B1 and C1 (Kd = 18 ± 1 and 6.4 ± 0.6 µM, 
respectively) and the i,i+8 peptide, D1 (Kd = 15 ± 1 µM), showed 
weaker binding to Ctf4 (Figure 2A). 
As the Sld5 peptide A1, stapled at positions i, i+6, showed 
the strongest binding to Ctf4CTD, it was further investigated using 
our double-click stapling strategy to explore different staple 
scaffolds. The stapled peptide A2, which bears a linear aliphatic 
staple linkage (staple 2 in Scheme 2), was able to bind to Ctf4CTD 
with a Kd of 0.32 ± 0.02 µM (Figure 2B and Supplementary figure 
1). Alternative aliphatic staples 3 and 4 (Scheme 2) were also 
investigated: the corresponding stapled peptides A3 and A4 
bound to Ctf4 CTD with comparable Kd values of 1.3 ± 0.2 µM, 
better than the wild-type peptide but not as tight as A2 (Figure 2B). 
However, the linkers in A3 and A4 provide attachment points for 
chemical derivatisation of the staple which could be exploited for 
instance to improve cell permeabilization[29,31], while still retaining 
dissociation constants that are 2.7-fold stronger than the wild-type 
peptide. 
FP analysis of A2 showed that its binding to Ctf4CTD was one 
order of magnitude stronger than the wild-type peptide (Sld51-19). 
To confirm this improvement in the binding strength to Ctf4, we 
performed a competition experiment, challenging the bound 
fluorescently-labelled A2 peptide with unlabelled Sld51-19 or A2 
peptides (Figure 2C). The experiment showed that the A2 peptide 
is a better competitor for Ctf4 binding (IC50 of 1.33 ± 0.22 µM) than 
the wild-type Sld51-19 peptide (IC50 of 7.74 ± 1.18 µM). 
In the crystal structure of Ctf4CTD bound to the Sld5 CIP, the 
peptide adopts a two-turn -helical fold[13] (Figure 1A). We set out 
to investigate whether the Sld5 CIP is intrinsically unfolded in 
solution, and whether stapling might promote -helical structure 
in the A2 peptide that could explain its higher affinity for Ctf4. 
Circular dichroism (CD) analysis of Sld51-19 and A2 peptides 
indicated that they are largely unfolded in aqueous buffer, and that 
addition of tri-fluoroethanol (TFE) induced partial -helix 
formation in both peptides, as expected (Supplementary figure 2).  
In the absence of TFE however, we noticed a 14% 
difference in -helical content between the two peptides: whereas 
the wild-type Sld5 peptide is only 7% helical, the -helix content 
of A2 is 21%, three times higher than wild-type. Conversely, the 
CD analysis of the diazido-peptide A, the modified peptide prior to 
double-click chemistry, suggests that its helical content is only 3% 
(Supplementary figure 2). The physical linkage between i and i+6 
residues in the A2 peptide might be responsible for its higher 
intrinsic α-helical content, which would account for its stronger 
binding to Ctf4. 
To determine whether the mode of binding of A2 to Ctf4CTD 
was as originally observed in the Ctf4CTD - Sld5 CIP structure[13] 
and to elucidate the conformation of the stapled Sld5 peptide 
bound to Ctf4CTD, we determined the X-ray crystal structure of the 
Ctf4CTD - A2 complex, by soaking the stapled peptide in crystals 
of Ctf4CTD (Supplementary table 1). The coordinates and structure 
factors are deposited in the Protein Data Bank under accession 
code 5NXQ. Interestingly, a reproducible improvement in 
diffraction properties of the Ctf4CTD crystals was observed upon  
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soaking of the A2 peptide, which was not observed in the original 
soaking experiments with the Sld5 CIP, providing further, indirect 
evidence that A2 has a stronger affinity for Ctf4CTD.  
Figure 3. X-ray crystal structure of Ctf4CTD bound to the A2 peptide. A Side view 
of the structure drawn as ribbons, in khaki (A2) or purple (Ctf4). The side chains 
of amino acids discussed in the text are shown as sticks. The stapling positions 
i and i+6 are indicated by arrows. B Top view of the structure, drawn and 
coloured as in A. 
The experiment showed that A2 binds Ctf4CTD in an identical 
way to the wild-type Sld5 CIP[13] (Figure 3). In the structure, the 
bis-triazole linker is located on the opposite side of the A2 peptide 
relative to the Sld5 CIP - Ctf4CTD interface, thus achieving the 
conformation that had originally been planned. The linker is fully 
exposed to solvent and must therefore cause higher affinity of the 
A2 peptide by facilitating the adoption of the correct helical 
conformation for Ctf4CTD binding. The structure further shows that 
the triazole ring proximal to stapling position i packs against the 
salt link between Sld5 D7 and Ctf4 R904, providing further 
stabilisation of the stapled Sld5 CIP - Ctf4CTD interface. 
Surprisingly, the presence of the non-orthodox i,i+6 staple caused 
no significant difference in conformation between the Ctf4-bound 
A2 and Sld5 peptides (Figure 4). 
Figure 4. Superposition of the Ctf4CTD structure bound to the stapled A2 peptide 
and to the wild-type Sld5 CIP (PDB id 4c95). Ctf4CTD is shown as a light-brown 
ribbon, and the CIP peptides are drawn as sticks, in cyan (A2) and green (Sld5). 
Our structural analysis offers a possible rationale for the 
different affinities resulting from the choice of stapling positions in 
the CIP sequence. The size of the linker is unlikely to be a major 
factor in the reduced affinity of peptides B1, C1 and D1, where the 
interval between stapling positions is larger, because the spacers 
of staples 1 and 2 were shown to give optimal binding affinity for 
i,i+7 stapling, compared to longer spacers[29,36]. Thus, the weaker 
binding of the B1, C1 and D1 peptides relative to A1 might result 
from loss of favourable electrostatic interactions provided by D6 
and D13 (B1), E11 (C1) or D6 (D1) with the basic residues lining 
the hydrophobic core of the CIP-binding site in Ctf4 (Figure 1B, 
C). In the case of B1, an unfavourable steric effect caused by the 
position of the staple might have also contributed to the loss of 
affinity.  
We next investigated the ability of the wild-type Sld5 CIP 
and its stapled version A2 to interfere with the interaction between 
GINS and Ctf4CTD. For this experiment, increasing amounts of 
peptide were incubated with reconstituted Ctf4CTD - GINS complex 
and the samples were analysed by analytical gel filtration 
(Supplementary figure 3). Addition of both wild-type Sld5 and 
stapled A2 peptide caused a partial disruption of the Ctf4CTD - 
GINS complex in a concentration-dependent manner, as 
demonstrated by the reduction in peak size for the Ctf4CTD - GINS 
complex and increase in the amount of free GINS. The disruptive 
effect of the Sld5 CIP peptides was noticeable but limited; the 
incomplete dissociation of the complex is in agreement with 
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previous evidence indicating that the interaction surface between 
GINS and Ctf4CTD extends beyond the Sld5-CIP binding site[13]. 
Nevertheless, at the highest concentration tested in the assay, the 
stapled peptide A2 was nearly twice more efficient than the wild-
type Sld5 CIP (Supplementary figure 3). 
Figure 5. The Sld5 CIP displaces Pol 1 (yeast Pol ) from the replisome in yeast 
cell extracts. A TAP-SLD5 budding yeast cells (YSS47) were grown at 30 °C, 
arrested in G1 phase with mating pheromone, and then released into S phase 
for 20 minutes. DNA content was measured by flow cytometry.  B The TAP-
tagged Sld5 subunit of the CMG helicase was then isolated from cell extracts 
by immunoprecipitation in presence of the indicated stapled peptides or controls 
(the peptides were all dissolved in DMSO), and the indicated proteins were 
detected by immunoblotting with the corresponding antibodies. Note that the 
CMG helicase comprises Cdc45, the GINS hetero-tetramer (made up of the 
Psf1, Psf2, Psf3 and Sld5 subunits) and the MCM2-7 hetero-hexamer. 
Our previous work showed that the CIP of Pol1, the catalytic 
subunit of yeast DNA polymerase  (Pol  is required for Pol1 
to associate with Ctf4 in vitro[13]. Moreover, mutations in the Pol1 
CIP lead to displacement of Pol  from the replisome in yeast 
cells[13]. To explore whether it is possible to develop inhibitors of 
the interaction of Ctf4 with clients such as Pol1, we assayed the 
ability of the stapled or natural versions of the Sld5 CIP to disrupt 
the association of Pol  with the replisome in yeast cell extracts.  
After synchronising budding yeast cells in S-phase (Figure 5A), 
cell extracts were generated and incubated with or without Sld5-
CIP or control peptides, before isolation of the replisome by 
immunoprecipitation of a tagged version of the Sld5 subunit of the 
CMG helicase (Figure 5B).   
Whereas none of the peptides disrupted the CMG helicase 
or its interactions with partners such as Csm3, the Sld5 CIP 
peptides specifically displaced Pol  from the replisome.  Notably, 
the stapled A2 version of the Sld5 CIP was more effective at lower 
concentrations than the wild-type Sld5 CIP (Figure 5B). In 
contrast to the complete disruption achieved for the association of 
Pol  with the replisome, the stapled version of the Sld5 CIP had 
a more modest effect on the association of Ctf4 with the CMG 
helicase (Figure 5B). This is consistent with our past data showing 
that mutation of the Sld5 CIP does not displace Ctf4 from CMG[13], 
presumably reflecting the more extensive nature of the interaction 
between Ctf4 and CMG. Nevertheless, these data indicate that 
the stapled Sld5 CIP can efficiently inhibit the association of 
replisome-bound Ctf4 with client proteins such as Pol . 
Our preliminary evidence indicates that the A2 peptide 
displayed limited take-up in yeast cells, which prevented us from 
assessing its ability to interfere with Ctf4 function in vivo. However, 
the method allows for a simple approach to garner cell 
permeability by modification of the staple[29,31]. Future work will be 
required to fully explore the potential of stapled peptides to inhibit 
Ctf4 function in cells and tissues, perhaps by systematic 
derivatisation of the stapling group, which is facilitated by our two-
component double-click stapling technique. Furthermore, our 
proof-of-concept work with stapled peptides will serve to inspire 
the development of small-molecule inhibitors with different 
pharmacological properties.  
The role of Ctf4 as a hub in the replisome, coupling DNA 
synthesis to diverse molecular processes that pertain to 
chromosome replication and segregation, is likely to be 
conserved in diverse eukaryotic species. For example, the human 
orthologue of Ctf4 (also known as AND-1 or WDHD1) shares 
sequence conservation, domain structure, oligomerisation state 
and physiological roles with its yeast orthologue. It is therefore 
likely that human CTF4 will represent an attractive therapeutic 
target in the treatment of cancers carrying defects in CIN genes, 
and our work raises the prospect that it will be possible to design 
inhibitors of the interaction of human CTF4 with its client proteins.  
Future efforts will be devoted to developing appropriate 
strategies, including the stapled-peptide approach demonstrated 
here, to target the biochemical function of CTF4 in human cells. 
As the type of peptide-protein interaction involving Ctf4 and its 
partner proteins is likely to represent a paradigm for the dynamic 
functional architecture of the replisome, such an approach might 
also be applicable to other instances of PPI between components 
of the human replisome. 
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Interfering with the replisome.  
The replisome hub protein Ctf4 
represents an attractive potential 
target for development of cancer 
therapeutics. Development of 
stapled peptides that disrupt the 
interaction of Ctf4 with its client 
proteins in the replisome provides 
proof-of-principle evidence of how 
this can be achieved. 
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